Neuralink Pivots to Speech BCIs After Motor Bet Falls Behind
Get the Tech newsletter
Daily tech — startups, AI labs, chips, the launches that shape the next decade. Free.
- Neuralink is pivoting from motor BCIs to speech restoration BCIs, launching trials in May at Cleveland Clinic Abu Dhabi and in October at the University of Texas Southwestern Medical Center, after competitors achieved 97% accuracy in speech decoding for a 45-year-old ALS patient by 2024.
- Elon Musk had promised Neuralink would deliver 'superhuman abilities' and minds merged with AI, but the company's pivot toward speech restoration signals a course-correction toward conventional medical assistance rather than human enhancement.
- Paradromics CEO Matt Angle argued that Neuralink made a strategic mistake by focusing on motor BCIs, saying speech is the better first application because 'being able to talk to your loved ones again' provides the biggest quality-of-life gains.
- UC Davis researcher Sergey Stavisky, a former motor BCI researcher who pivoted to speech in 2019, countered that Neuralink didn't make the wrong bet in 2016, since academic motor BCI trials had matured enough to build useful medical devices with better hardware.
- Brad Smith, an ALS patient using Neuralink's motor BCI, typed a 16-word response in one minute and 17 seconds — illustrating the speed ceiling that speech BCIs may solve by translating brain signals directly into words.
- Neuralink hired a former FDA medical devices director to head its medical affairs and announced 'high-volume production' of devices in a December 31 X post, with the article noting Musk's production predictions 'need to be taken with a grain of salt.'
- Spero Koulouras, an ALS patient who is 'effectively quadriplegic and mute,' told The Verge he would choose a motor BCI 'by a mile,' underscoring that patients' needs vary and that both speech and motor BCIs should coexist.
Why it matters: Neuralink's pivot marks a strategic concession to competitors like Paradromics that bet on speech from the start. With fewer than several dozen people worldwide having used motor BCIs, the company is realigning with proven patient need — where speech trials are already posting 97% accuracy in ALS patients — over Musk's transhumanist vision.
